<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04610879</url>
  </required_header>
  <id_info>
    <org_study_id>CASTLE</org_study_id>
    <secondary_id>2018-003893-29</secondary_id>
    <secondary_id>RP-PG-0615-20007</secondary_id>
    <nct_id>NCT04610879</nct_id>
  </id_info>
  <brief_title>Changing Agendas on Sleep, Treatment and Learning in Epilepsy</brief_title>
  <acronym>CASTLE</acronym>
  <official_title>Randomised Factorial Design Controlled Trial Comparing Carbamazepine, Levetiracetam or Active Monitoring Combined With or Without Sleep Behaviour Intervention in Treatment Naive Children With Rolandic Epilepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>King's College Hospital NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Liverpool</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bangor University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Edge Hill University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oxford Brookes University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>King's College London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rolandic epilepsy (RE) is the most common type of epilepsy. Children with RE have seizures&#xD;
      and can often find that their learning, sleep, behaviour, self-esteem and mood are affected.&#xD;
&#xD;
      As part of standard NHS care, children diagnosed with RE may be treated with standard&#xD;
      anti-epileptic medicines, like carbamazepine, or no medicine at all. The medicines used to&#xD;
      treat epilepsy often slow down a child's thinking and learning. In the past, doctors believed&#xD;
      this was an acceptable price to pay to reduce seizures. However, with RE, where the seizures&#xD;
      usually stop in teenage years, investigators do not know if it is better to treat these&#xD;
      children with medicines or not, especially if the medicines might have a negative effect on&#xD;
      their learning.&#xD;
&#xD;
      A newer medicine called levetiracetam has also been found to work in children with RE and has&#xD;
      shown less problems with thinking and learning in adults. However, it is still no known if&#xD;
      this is also the case for children and it has not been proven which of the three options&#xD;
      (carbamazepine, levetiracetam or no treatment) would be best for RE patients. The CASTLE&#xD;
      study aims to find this out.&#xD;
&#xD;
      In addition, it has been found that seizures often happen when a child has had poor sleep and&#xD;
      they often come at night or early in the morning. It has been shown that sleep can be&#xD;
      improved through practice without the need of medicines. There are established guidelines to&#xD;
      help toddlers go to sleep, but nothing available that helps young people with epilepsy and&#xD;
      their parents improve their sleep quality. In the CASTLE study, a sleep training plan has&#xD;
      been developed for children with epilepsy and the trial aims to find out whether following&#xD;
      this sleep training plan results in less seizures than using no sleep training at all.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial is a phase IV randomised factorial design controlled trial comparing carbamazepine,&#xD;
      levetiracetam or active monitoring combined with or without sleep behaviour intervention. A&#xD;
      factorial trial design has been used as this approach enables the efficient simultaneous&#xD;
      investigation of AED (carbamazepine; levetiracetam; no AED) and sleep behaviour intervention&#xD;
      (vs standard care) by including all participants in both analyses. In a factorial trial it is&#xD;
      also possible to consider both the separate effects of each intervention and the benefits of&#xD;
      receiving both interventions together (for example levetiracetam and sleep intervention).&#xD;
&#xD;
      The CASTLE trial will take place in NHS out-patient paediatric epilepsy and general&#xD;
      paediatric clinics in the United Kingdom (UK).&#xD;
&#xD;
      Once consent has been obtained from the appropriate adult, and assent from the child if&#xD;
      appropriate, by the delegated member of the research team the eligibility assessments will be&#xD;
      completed, full eligibility confirmed (confirmation must be by a medically qualified doctor)&#xD;
      and baseline data will be collected prior to randomisation.&#xD;
&#xD;
      Randomisation will be performed via a web based tool accessed by research team at site. This&#xD;
      system is generated centrally by the Clinical Trial Research Centre (CTRC) using a computer&#xD;
      algorithm concealed from the investigators and research teams/trial management group. In&#xD;
      order to balance the groups, minimisation for variables believed to influence disease outcome&#xD;
      and end points will be built into the randomisation algorithm.&#xD;
&#xD;
      Participants will be randomised to treatment with carbamazepine, levetiracetam or active&#xD;
      monitoring. Where randomised to drug treatment, the randomised treatment should ideally begin&#xD;
      on the day of randomisation or within 14 days of randomisation at the latest. Randomised&#xD;
      treatment will continue for a minimum of 12 months and a maximum of 48 months. All treatments&#xD;
      will be procured, prescribed and issued as per routine NHS practice.&#xD;
&#xD;
      Clinical data capture will be in the form of paper copies of Case Report Forms (CRFs) that&#xD;
      will be returned as an on-going process from each centre to the CTRC. Patient/parent reported&#xD;
      data will be collected directly on paper at each outpatient visit with the exception of&#xD;
      CANTAB, which will be collected on iPads at the centre.&#xD;
&#xD;
      All trial documents (except raw Hospital Episode Statistics (HES) from NHS digital that will&#xD;
      only be retained for 1 year) will be retained for 25 years from the End of Trial. The PI at&#xD;
      each investigational centre must make arrangements to store the essential trial documents,&#xD;
      (as defined in Essential Documents for the Conduct of a Clinical Trial (ICH E6, Guideline for&#xD;
      Good Clinical Practice)) including the ISF, until the CTRC informs the investigator that the&#xD;
      documents are no longer to be retained&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Following the internal pilot, the study did not meet prespecified stop/go criteria for&#xD;
    continuation.&#xD;
  </why_stopped>
  <start_date type="Actual">August 2, 2019</start_date>
  <completion_date type="Actual">September 23, 2020</completion_date>
  <primary_completion_date type="Actual">September 23, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>The trial is a phase IV randomised factorial design controlled trial comparing carbamazepine, levetiracetam or active monitoring combined with or without sleep behaviour intervention. We have used a factorial trial design as this approach enables the efficient simultaneous investigation of anti-epileptic drug (AED) (carbamazepine; levetiracetam; no AED) and sleep behaviour intervention (vs standard care) by including all participants in both analyses. In a factorial trial it is also possible to consider both the separate effects of each intervention and the benefits of receiving both interventions together (for example levetiracetam and sleep intervention).</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to 6-month seizure remission</measure>
    <time_frame>Up to 48 months</time_frame>
    <description>To determine if carbamazepine or levetiracetam are superior to no anti-epileptic drugs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline to total sleep problem score as measured by the Children's Sleep Habits Questionnaire (CSHQ)</measure>
    <time_frame>At 3 months</time_frame>
    <description>To determine if a Parent-Based Sleep intervention is superior to standard care</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total costs measured in Quality-Adjusted Life Years (QALYs)</measure>
    <time_frame>At 0, 3, 12, 24, 36 and 48 months</time_frame>
    <description>To estimate the cost-utility of carbamazepine, levetiracetam and PBS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time taken from randomisation to decision by child, parent or treating physician to be withdrawn from treatment due to inadequate seizure control or unacceptable adverse reactions</measure>
    <time_frame>At 3, 6,12, 24, 36 and 48 months</time_frame>
    <description>To compare time to treatment failure due to inadequate seizure control or unacceptable adverse reactions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time taken from randomisation to decision by child, parent or treating physician to be withdrawn from treatment due to inadequate seizure control</measure>
    <time_frame>At 3, 6,12, 24, 36 and 48 months</time_frame>
    <description>To compare time to treatment failure due to inadequate seizure control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time taken from recruitment to decision by child, parent or treating physician to be withdrawn from trial due to unacceptable adverse reactions</measure>
    <time_frame>At 3, 6,12, 24, 36 and 48 months</time_frame>
    <description>To compare time to treatment failure due to unacceptable adverse reactions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first seizure based on seizure report</measure>
    <time_frame>At 3, 6,12, 24, 36 and 48 months</time_frame>
    <description>To compare time to first seizure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to 12-month seizure remission based on seizure report</measure>
    <time_frame>At 3, 6,12, 24, 36 and 48 months</time_frame>
    <description>To compare time to 12-month remission from seizures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total sleep problem score as measured by the Children's Sleep Habits Questionnaire (CSHQ)</measure>
    <time_frame>At 12, 24, 36 and 48 months</time_frame>
    <description>To determine if a Parent-Based Sleep intervention is superior to standard care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total score in three chosen assessments delivered by the Cambridge Neuropsychological Test Automated Battery (CANTAB)</measure>
    <time_frame>At 0, 3, 6,12, 24, 36 and 48 months</time_frame>
    <description>To compare measures of cognition across the different treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score change in Health Related Quality of Life in Children with Epilepsy - Child self-report scale (CHEQOL)</measure>
    <time_frame>At 0, 12, 24, 36 and 48 months</time_frame>
    <description>To compare Health Related Quality of Life across the different treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total score on Strengths and Difficulties Questionnaire (SDQ)</measure>
    <time_frame>At 0, 12, 24, 36 and 48 months</time_frame>
    <description>To compare measures of children's behaviour across the different treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Records of adverse reactions</measure>
    <time_frame>At 3, 6, 12, 24, 36 and 48 months</time_frame>
    <description>To identify any adverse reactions and their rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score changes in Child Health Utility instrument (CHU9D)</measure>
    <time_frame>At 0, 3, 12, 24, 36 and 48 months</time_frame>
    <description>To estimate child health utilities and Quality-Adjusted Life Years (QALYs) across the different treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score changes in EQ-5D-Y</measure>
    <time_frame>At 0, 3, 12, 24, 36 and 48 months</time_frame>
    <description>To estimate child health utilities and Quality-Adjusted Life Years (QALYs) across the different treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D-5L score change</measure>
    <time_frame>At 0, 3, 12, 24, 36 and 48 months</time_frame>
    <description>To estimate health utilities and Quality-Adjusted Life Years (QALYs) across parents in the different treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score changes in Parental Self-Efficacy Measure (PSAM)</measure>
    <time_frame>At 0, 3, 12, 24, 36 and 48 months</time_frame>
    <description>To compare parenting self-efficacy across the different treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total sickness related school absences (days)</measure>
    <time_frame>At 0, 3, 6, 12, 24, 36 and 48 months</time_frame>
    <description>To compare sickness related school absences across the different treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resource Use Questionnaire</measure>
    <time_frame>At 3, 12, 24, 36 and 48 months</time_frame>
    <description>To determine the costs to the National Health Service (NHS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Episode Statistics (HES) Data</measure>
    <time_frame>48 months, measured for the participant's study duration</time_frame>
    <description>To determine the costs to the National Health Service (NHS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Level Information and Costing System (PLICS) Data</measure>
    <time_frame>48 months, measured for the participant's study duration</time_frame>
    <description>To determine the costs to the National Health Service (NHS)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Summary of actigraphy variables (total sleep time/sleep latency/sleep efficiency) averaged over a 1-week period</measure>
    <time_frame>1 week actigraphy (arranged centrally via Oxford unit) at baseline, 3 and 12 months</time_frame>
    <description>To determine which sleep parameters change in primary carer and child dyads in different treatment groups</description>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Rolandic Epilepsy</condition>
  <arm_group>
    <arm_group_label>Carbamazepine plus sleep intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Carbamazepine plus standard care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Levetiracetam plus sleep intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Levetiracetam plus standard care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>No AED plus sleep intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>No AED plus standard care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbamazepine</intervention_name>
    <description>Treatment will be procured, prescribed and issued as per routine NHS practice. Generics can be prescribed.</description>
    <arm_group_label>Carbamazepine plus sleep intervention</arm_group_label>
    <arm_group_label>Carbamazepine plus standard care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levetiracetam</intervention_name>
    <description>Treatment will be procured, prescribed and issued as per routine NHS practice. Generics can be prescribed.</description>
    <arm_group_label>Levetiracetam plus sleep intervention</arm_group_label>
    <arm_group_label>Levetiracetam plus standard care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Parent based sleep (PBS) intervention</intervention_name>
    <description>The PBS intervention is an e-learning package for parents/primary carers and children with epilepsy. The PBS intervention offers parents education about normal sleep, advice about sleep-promoting practices and targeted strategies parents can employ to help their children to ''learn'' an appropriate set of sleep behaviours/habits and/or to unlearn inappropriate sleep behaviours.</description>
    <arm_group_label>Carbamazepine plus sleep intervention</arm_group_label>
    <arm_group_label>Levetiracetam plus sleep intervention</arm_group_label>
    <arm_group_label>No AED plus sleep intervention</arm_group_label>
    <other_name>CASTLE Online Sleep Intervention (COSI)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Children diagnosed with RE (see International League Against Epilepsy Diagnostic&#xD;
             Manual at https://www.epilepsydiagnosis.org/syndrome/ects-overview.html)&#xD;
&#xD;
          2. EEG showing focal sharp waves with normal background (see International League Against&#xD;
             Epilepsy Diagnostic Manual at&#xD;
             https://www.epilepsydiagnosis.org/syndrome/ects-eeg.html)&#xD;
&#xD;
          3. Aged â‰¥5 years and &lt;13 years at the time of randomisation&#xD;
&#xD;
          4. Currently untreated with antiepileptic drugs&#xD;
&#xD;
          5. Written informed consent received from person with parental responsibility/legal&#xD;
             representative.&#xD;
&#xD;
          6. Family have an email address and regular internet access (for online sleep&#xD;
             intervention)&#xD;
&#xD;
          7. Parent and child are to have a good understanding of the English language&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known contraindication to any of the trial drugs&#xD;
&#xD;
          2. Previously treated for epilepsy with antiepileptic drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>King's College Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE5 8EF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tameside Hospital</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Whiston Hospital</name>
      <address>
        <city>Whiston</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>July 9, 2019</study_first_submitted>
  <study_first_submitted_qc>October 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2020</study_first_posted>
  <last_update_submitted>October 26, 2020</last_update_submitted>
  <last_update_submitted_qc>October 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Epilepsy, Rolandic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carbamazepine</mesh_term>
    <mesh_term>Levetiracetam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>The current data sharing plans for this study are unknown and will be available at a later date</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

